Paul Scigalla - 18 Oct 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
Chief Medical Officer
Signature
/s/ Sean Ryder, Esq., Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
18 Oct 2024
Transactions value $
$0
Form type
4
Filing time
21 Oct 2024, 17:05:05 UTC
Previous filing
25 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Stock Option (right to buy) Award $0 +16,666 $0 16,666 18 Oct 2024 Common Stock 16,666 $6 Direct F1
transaction GNLX Stock Option (right to buy) Award $0 +16,666 $0 16,666 18 Oct 2024 Common Stock 16,666 $6 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 100% of the shares subject to the Option shall vest on December 31, 2024.